INTRODUCTION

As of June 21, 2021, approximately 318 million COVID-19 vaccine doses have been administered in the United States (U. S).[1] The Pfizer-BioNTech COVID-19 mRNA vaccine received Emergency Use Authorization from the U. S. Food and Drug Administration for individuals ≥16 years in December 2020 and those 12–15 years in May 2021.[2] While the Pfizer-BioNTech COVID-19 vaccine trials included over 43,000 participants ≥16 years in Phase 2/3, the number of participants in the younger age groups was limited. According to the Pfizer-BioNTech COVID-19 mRNA Vaccine Fact Sheet, Phase 2/3 included 138 and 145 adolescents 16 and 17 years of age in the vaccine and placebo groups, respectively. There were 2260 participants aged 12–15 years: 1131 and 1129 in the vaccine and placebo groups, respectively.[2] It is possible that rare adverse events could manifest when administered to a larger population. We report three healthy male adolescents diagnosed with myocarditis following Pfizer-BioNTech COVID-19 vaccination, confirmed on cardiac magnetic resonance imaging (CMR).

CASE REPORTS

Case 1

A 17-year-old male with a history of asthma presented to the emergency department (ED) with chest pain 2 days after receiving his second Pfizer-BioNTech COVID-19 vaccine. He initially developed fever, chills, malaise, myalgia, nausea, and vomiting, followed by sharp, central chest pain and dyspnea. The chest pain did not respond to albuterol or ibuprofen. There was no preceding upper respiratory infection (URI) or other gastrointestinal (GI) symptoms. Laboratory and clinical data are summarized in Table 1. Initial troponin was 8.1 ng/mL (normal <0.05 ng/mL). Electrocardiogram (ECG) was consistent with myopericarditis [Figure 1]. An
echocardiogram demonstrated normal biventricular size/function and proximal coronary arteries. A chest computed tomography was negative for pulmonary embolism. Nitroglycerin was ineffective and resulted in transient hypotension that self-resolved. He was transferred to our center, received 2 g/kg of intravenous immunoglobulin (IVIG) and was started on steroids and aspirin. Colchicine was added for ongoing chest pain, which provided symptomatic relief. CMR was consistent with myocarditis: late-gadolinium enhancement (LGE) at the left ventricular (LV) inferior wall, myocardial edema, and hyperemia at the mid-LV anterior wall [Figure 2].

As symptoms and troponin improved, aspirin was discontinued, and he was discharged after 6 days with exercise restrictions, a steroid taper, and colchicine for 2 weeks. At the 10-day follow-up, he had normal labs and echocardiogram.

Case 2

A 16-year-old previously healthy male presented to the ED with chest pain 3 days after receiving his first dose of Pfizer-BioNTech COVID-19 vaccine. He had a subjective fever 1 day after vaccination. The following day, he developed sharp left-sided chest pain, exacerbated by physical activity. He was referred to our center, where an electrocardiogram (ECG) revealed sinus tachycardia (heart rate = 102 bpm), T-wave inversion in lateral leads, and diffuse ST-segment changes (ST-segment elevation in inferolateral leads and ST-segment depression in aVR and V1) [Figure 1].

Table 1: Laboratory and clinical data

|                     | Case 1                   | Case 2                   | Case 3                   |
|---------------------|--------------------------|--------------------------|--------------------------|
| Presentation after dose | 2                        | 1                        | 2                        |
| Previous COVID-19 infection | No                       | Yes                      | No                       |
| Troponin (initial/peak) | 8.1/12.5 (normal <0.05 ng/mL) | 13.3/13.3 (normal <0.05 ng/mL) | 4.9/27.7 (normal <0.05 ng/mL) |
| CRP (initial/peak) | 75/87 (normal 0.1-1.7 mg/L) | Initial: 60 (High-sensitivity, normal <8.1 mg/L) | Peak: 55 (0.1-1.7 mg/L) |
| WBC on presentation | 12 (normal 4.5-13.2 x10^9/L) | 7.4                      | 13.6                     |
| ALC* on presentation (%) | 15 (normal 20-70)          | 27                       | 16                       |
| COVID-19 PCR | Negative                  | Negative                  | Negative                  |
| COVID-19 Antibody (IgG against nucleocapsid protein) | Negative                  | Positive 8.2 (normal <0.8, intermediate 0.8-1, positive >1) | Negative                  |
| Treatments | IVIG 2 g/kg                | 2 g/kg                   | 2 g/kg                   |
| Aspirin | Yes                      | Yes                      | Yes                      |
| Steroids | Steroid taper             | Steroid taper            | Steroid taper            |
| Outcome | Recovery                  | Recovery                 | Recovery                 |

ALC=Absolute lymphocytic count

Figure 1: ECG Case 1. ECG demonstrates sinus tachycardia (heart rate =102 bpm), T-wave inversion in lateral leads, and diffuse ST-segment changes (ST-segment elevation in inferolateral leads and ST-segment depression in aVR and V1). ECG: Electrocardiogram
by deep breathing, with radiation to the left upper extremity. There were no preceding URI or GI symptoms. Notably, he had a mild COVID-19 infection 5 months before presentation. He had a normal ECG and troponin-I of 13.3 (normal <0.05 ng/ml) on presentation [Table 1]. An echocardiogram showed normal biventricular size/function and proximal coronary arteries. During IVIG (2 g/kg) infusion, he had acute worsening of chest pain, marked ST elevation, and troponin rise to 27.7 ng/mL [Table 1]. He was given nitroglycerin, aspirin, and morphine and started on steroids. CMR demonstrated LGE involving the inferolateral wall and hypokinesis in the mid-ventricular level inferolateral wall. As troponin downtrended and symptoms improved, he was discharged with exercise restrictions, aspirin, and a steroid taper after 7 days of hospitalization. Troponin-I was 0.29 (normal <0.09 ng/mL) 4 days after discharge, and follow-up echocardiogram was normal.

**DISCUSSION**

In this case series, we report three male adolescents with CMR-confirmed myocarditis diagnosed shortly after receiving Pfizer-BioNTech COVID-19 vaccine. The estimated incidence of myopericarditis after the second dose of the Pfizer mRNA COVID-19 vaccine is around 0.01% (12–15 years) and 0.008% (16–17 years).[3] A recent multicenter case series reported this entity in seven children, and shortly thereafter Shaw et al. reported two adolescents.[4,5] In the Marshall et al. series, all cases followed the second dose of the vaccine. Interestingly, two cases in the Shaw et al. series and one of our cases had myocarditis following the first vaccine dose. All three of these patients had documented previous COVID-19 infection. An increased immunogenic response may be a factor in patients with previous COVID-19 infection receiving COVID-19 vaccination and warrants further study.

Given myocarditis is a potentially life-threatening condition, it must be diagnosed promptly.[6] CMR is the gold standard noninvasive diagnostic modality for diagnosing myocarditis and can differentiate ischemic versus nonischemic inflammatory processes. In adults, parametric T1, T2, and extracellular volume mapping techniques are well-validated for diagnosing myocarditis. However, the pediatric evidence for parametric mapping is much more limited, and currently, applying the original Lake Louise Criteria yields higher sensitivity to the CMR diagnosis of pediatric myocarditis.[7] Children with myocarditis occasionally present with symptoms mimicking acute coronary syndrome: chest pain, dyspnea, elevated cardiac enzymes, and ECG abnormalities.[8] In these instances, it is important to keep myocarditis high on the differential diagnosis as

---

**Figure 2**: CMR with original Lake Louise Protocol Case 1. (a) T2-weighted black-blood sequence with >2:1 increase in myocardial signal intensity compared to skeletal muscle at the mid-LV, anterior wall. Positive findings were consistent with myocardial edema. (b) T1-weighted TSE sequence with >45% increase in signal intensity postcontrast at the mid-LV. Positive for early gadolinium enhancement, indicating hyperemia. (c) Late-gadolinium enhancement, signifying fibrosis or scar (green arrow), was noted on several slices at the LV inferior wall. CMR: Cardiac magnetic resonance imaging, TSE: Turbo spin echo, LV: Left ventricular wall.
opposed to ischemic coronary disease, which is rare in children.

**CONCLUSIONS**

COVID-19 vaccine-related myocarditis is an emerging entity that must be closely examined and reported to the Vaccine Adverse Event Reporting System in the U. S. All published cases to date have had good clinical outcomes in the short term, and it is vitally important to collect long-term data in this population. It is crucial to remember this entity can mimic acute coronary syndrome, to avoid unnecessary procedures for adolescents in whom ischemic coronary disease is exceedingly rare. CMR is the gold standard noninvasive test that can help establish the diagnosis of myocarditis. Larger studies are needed to further delineate the association between the Pfizer-BioNTech COVID-19 vaccine and myocarditis. We recommend following Centers for Disease Control guidelines and updates.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Acknowledgment**

Drs. Kimberly Kallianos and Yoo Jin Lee coperformed the magnetic resonance imagings for Cases 1 and 2 with Dr. Anwar.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Coronavirus (COVID-19) vaccinations. Our World in Data. Available from: https://ourworldindata.org/covid-vaccinations?country=USA. [Last accessed on 2021 Jun 21].
2. Pfizer-BioNTech. Full Emergency Use Authorization (EUA) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=14471&format=pdf&page=13. [Last accessed on 2021 Jun 19].
3. Schauer J, Buddhe S, Colyer J, Sagiv E, Law Y, Mallenahalli Chikkabyrappa S, et al. Myopericarditis after the pfizer messenger ribonucleic acid coronavirus disease vaccine in adolescents. J Pediatr 2021;238:317-20.
4. Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-Biontech COVID-19 vaccination. Pediatrics 2021;148:e2021052478.
5. Shaw KE, Cavalcante JL, Han BK, Gössl M. Possible association between COVID-19 vaccine and myocarditis: Clinical and CMR findings. JACC Cardiovasc Imaging 2021;14:1856-61.
6. Simpson KE, Anwar S, Canter CE. Myocarditis. Moss and Adam’s Heart Disease. 10th ed. Philadelphia: Lippincott Williams & Wilkins (LWW); 2021.
7. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll Cardiol 2018;72:3158-76.